Physician profile
Heather M Mitchell
NPI 1326278466
$3,489.68
in general payments reported to CMS, 2019-2025
21 companies · $819 in 2025
The $819 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $638 · 2022: $519 · 2023: $506 · 2024: $1,008 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,333.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $955.97 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $619.07 | 2021-2025 | |
| Lilly USA, LLC | $346.09 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $229.43 | 2021-2025 | Trelegy Ellipta |
| Amgen INC. | $228.46 | 2021-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $223.61 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $189.63 | 2021-2024 | |
| Exact Sciences Corporation | $174.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105.80 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.94 | 2023-2024 | Jardiance |
| Medtronic, INC. | $80.84 | 2024-2025 | Intellis Adaptivestim, Inceptiv |
| Abbott Laboratories | $48.01 | 2024-2025 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $33.10 | 2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $30.67 | 2021 | |
| Madrigal Pharmaceuticals | $27.15 | 2025 | Rezdiffra |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $22.66 | 2024 | Rexulti |
| Grifols USA, LLC | $20.67 | 2024 | Prolastin-C Liquid |
| Genentech USA, INC. | $17.60 | 2021 | |
| Upsher-Smith Laboratories LLC | $16.43 | 2021 | |
| Sonex Health, INC. | $15.60 | 2024 | Sx-One Microknife |
| Cequr Corporation | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.